High dose oral cimaluptide can improve blood glucose control and weight loss

A new study found that compared with the minimum dose of 14 mg, the oral administration of 25 mg and 50 mg simaluptide once a day had better effects in reducing blood glucose levels and promoting weight loss. This new study is consistent with other studies that are promoting the use of oral GLP-1 receptor agonists as a treatment for obesity.

Diabetes is a progressive disease that affects the ability of people to control blood sugar levels. For many patients, over time, the disease will become more and more serious, and the blood glucose level will become more and more difficult to control. Glucagon like peptide-1 (GLP-1) receptor agonists, such as semaglutide, give patients more control in reducing blood glucose.

John busy, M.D., distinguished medical professor of Verne s. caviness, Department of Endocrinology and metabolism, and an international research team presented new findings on a new high-dose oral semaglutide formula. Their study published in the lancet found that compared with the minimum dose of 14 mg, the oral administration of 25 mg and 50 mg simaluptide once a day had better effects in reducing blood glucose levels and promoting weight loss.

"Low dose GLP-1 receptor agonists are very effective in reducing A1C or the average glucose level in the blood," said bath, who is also the co director of the NC transformation and Clinical Science Institute. "However, a high dose is really good for weight loss. On average, patients lost 8 kilograms (17.5 pounds) when taking 50 mg, which is almost twice the weight loss we saw at the lowest dose."

This new study is consistent with other studies that are promoting the use of oral GLP-1 receptor agonists as a treatment for obesity.

A total of 1606 participants, male with an average age of 58.2, participated in the third phase of the project approved by the regulatory authorities. Participants were randomly divided into three groups and were asked to take simaluptide orally once a day. Each group was given different doses of simaluptide, 14mg, 25mg or 50mg for 52 weeks.

Blood sugar levels are measured as a percentage, called glycosylated hemoglobin. According to the American Diabetes Association, the glycosylated hemoglobin (A1C) of most adult diabetic patients needs to be less than 7% to be considered healthy. The glycosylated hemoglobin of all participants in the trial was between 8.0% and 10.5%. The researchers found that compared with patients taking 14 mg of oral cimalutide, patients taking 25 mg and 50 mg of oral cimalutide were more likely to achieve the goal of A1C<7.0%.

Simaglutide (semaglutide for sale) also reduces weight by suppressing appetite. At the end of 52 weeks, participants taking 50 mg of oral cimaluptide lost an average of 17.5 pounds. Those who took 25 mg and 14 mg lost 14.8 pounds and 10 pounds, respectively.

During the experiment, the researchers noticed the side effects. The most common side effect is nausea, because the drug has an effect on stomach satiety. Some participants, especially those taking higher doses of 25 mg and 50 mg, experienced vomiting, diarrhea and/or constipation.